Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165,219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Fernández de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, Purdon TJ, Ponomarev V, Wendel HG, Brentjens RJ, Smith EL. Fernández de Larrea C, et al. Among authors: chen y. Blood Cancer Discov. 2020 Sep;1(2):146-154. doi: 10.1158/2643-3230.BCD-20-0020. Blood Cancer Discov. 2020. PMID: 33089218 Free PMC article.
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Jain T, et al. Among authors: chen y. Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509. Blood Adv. 2020. PMID: 32780846 Free PMC article.
BCMA-targeting approaches for treatment of multiple myeloma.
Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. Chen Y, et al. Panminerva Med. 2021 Mar;63(1):28-36. doi: 10.23736/S0031-0808.20.04121-X. Epub 2020 Sep 21. Panminerva Med. 2021. PMID: 32955181 Free article. Review.
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, Ong SY, Xu M; SGHMM1 Investigators; Chng WJ, Goh YT, Nagarajan C. Chen Y, et al. Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x. Blood Cancer J. 2021. PMID: 34480015 Free PMC article. Clinical Trial. No abstract available.
Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Ong SY, de Mel S, Chen YX, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AY, Hwang WY, Phipps C, Loh SM, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK. Ong SY, et al. Among authors: chen yx. Bone Marrow Transplant. 2016 Jul;51(7):933-7. doi: 10.1038/bmt.2016.43. Epub 2016 Mar 14. Bone Marrow Transplant. 2016. PMID: 26974274
165,219 results
You have reached the last available page of results. Please see the User Guide for more information.